Biotech Values

[ghmm]

I'm wondering if this could backfire and there could be more scrutiny on insurance companies and pbm's. I didn't like it years ago when my insurer tried to change me from one PPI to another (that they likely had a deal with). I wonder if at some point there isn't legislation requiring insurers to reimburse all medicine prescribed for the indication it was indicated for and not favor one drug over another if they are not chemically equivalent... I could see it getting worse (for insurance companies) in Biosimilars if a patient is forced to switch and then has an anaphylactic reaction.